TARUN PARVATANENI

Dr. TARUN PARVATANENI

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Cureus
Verified
Journal Article
Open access
PDF file
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
SSSushma srinivas
Sushma srinivas
KSKaushal Shah
Kaushal Shah
Rikinkumar S. PatelRikinkumar S. Patel
Rikinkumar S. Patel
Melatonin is a hormone produced by the pineal gland and is available over the counter for treating sleep problems in the pediatric population. We conducted a systematic review of randomized clinical trials (RCTs) on MEDLINE and included six studies that met our inclusion criteria. RCTs were conducted in patients from two to 18 years of age with a diagnostic and statistical manual of mental disorders (DSM)-IV diagnosis of autism spectrum disease (ASD) and/or attention-deficit hyperactivity disorder (ADHD) in both short-term and long-term RCTs ranging from eight-week to 52-week studies. The mean difference in the children’s sleep disorder showed statistically significant improvement in sleep duration and sleep latency onset compared to the placebo. Overall, a high response rate was observed in the melatonin group compared to the placebo in treating sleep problems in children. Melatonin is a well-tolerated and safe medication in the dose range of 2-10 mg/day in the child and adolescent population.

2 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
SSSushma srinivas
Sushma srinivas
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
RMRamkrishna Makani
Ramkrishna Makani
Rikinkumar S. PatelRikinkumar S. Patel
Rikinkumar S. Patel
Quetiapine is a second-generation antipsychotic (SGA) approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia, mania, and aggression in children and adolescents. It is also commonly used as an off-label medication to treat children and adolescents with bipolar depression, although the FDA has not approved quetiapine for this purpose. We conducted a systematic review of randomized clinical trials (RCTs) using the MEDLINE database and included two studies that met our inclusion criteria. Both RCTs were eight-week short-term studies that involved patients of 10-18 years of age with a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of bipolar disorder, depressed type. The mean difference in the Children's Depression Rating Scale-Revised (CDRS-R) score and the response and remission rates in the quetiapine group were not statistically significant when compared to the placebo group. A high placebo response rate proved that quetiapine was no better than the placebo in treating pediatric bipolar depression. Quetiapine proved to be a relatively safe drug with the most common side effects being headache, somnolence, gastric upset, and weight gain. There was a significant increase in triglyceride levels, but no other metabolic effects were reported. This calls for future studies with larger sample sizes and improved methodology to explore the efficacy of quetiapine and other SGAs for the management of pediatric bipolar depression.

21 November 2021 in Cureus
Verified
Journal Article
Open access
RSRaja Sundaramurthy
Raja Sundaramurthy
SBSuryakumar Balasubramanian
Suryakumar Balasubramanian
VGVithiya Ganesan
Vithiya Ganesan
PAPearl Aggarwal
Pearl Aggarwal
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
RSRaja Prahadeesh Saravanan
Raja Prahadeesh Saravanan
Background: In coronavirus disease 2019 (COVID-19) patients, risk stratification based on clinical presentation, co-morbid illness, and combined laboratory parameters is essential to provide an adequate, timely intervention based on an individual’s conditions to prevent mortality among cases. Methods: A retrospective observational study was carried out from June to October 2020, including all reverse transcription-polymerase chain reaction (RT-PCR) positive COVID-19 non-survivors and control group survivors randomly selected after age and sex matching. Clinical and demographic information was collected from the medical records. Categorical variables were expressed by frequency and percentage. To explore the risk factors associated with mortality, univariable and multivariable logistic regression models were used. Results and discussions: All non-survivors (n = 100) and 100 survivors (out of 1,018) were analyzed. Male gender (67.4%) was the independent risk factor for COVID-19 infection. Advanced age group, diabetes, cardiovascular, neurological, and hypertensive co-morbidities were statistically associated with mortality. Cardiac arrest and acute kidney injury (AKI) were the most common complications. Mortality is significantly associated with lymphopenia and raised lactate dehydrogenase (LDH), as shown by higher odds. In addition, raised neutrophils, monocytes, aspartate aminotransferase (AST), serum creatinine, interleukin 6 (IL-6), and C-reactive protein (CRP) are also significantly associated with mortality. The most common causes of death were respiratory failure (84%) and acute respiratory distress syndrome (77%). Of the non-survivors, 92% received corticosteroids, 63% were on high-flow nasal cannula oxygen therapy, 29% were mechanically ventilated, and 29% received tocilizumab. Conclusion: Serial monitoring of neutrophils, lymphocytes, D-dimer, procalcitonin, AST, LDH, CRP, IL-6, serum creatinine, and albumin might provide a reliable and convenient method for classifying and predicting the severity and outcomes of patients with COVID-19.

5 November 2024 in Blood
Verified
Journal Article
Closed access
KAKuldeepsinh Atodaria
Kuldeepsinh Atodaria
KSKeerthi Sripathi
Keerthi Sripathi
SVSamyukta Varma
Samyukta Varma
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
NBNavanita Biswas
Navanita Biswas
UPUrvish Patel
Urvish Patel
INTRODUCTION In the management of transplant-ineligible multiple myeloma (TIMM), therapeutic strategies are crucial for improving patient outcomes. Recent clinical trials have explored the efficacy of Quadruplet therapy and Triplet therapy in this context. Quadruplet therapy, involving an additional drug, has been proposed to offer enhanced benefits in overall survival and progression-free survival. AIM This meta-analysis aimed to evaluate the comparative effectiveness (overall survival [OS] and progression-free survival [PFS]) of Quadruplet vs Triplet therapy in TIMM regimens to inform clinical decision-making and optimize patient care. METHODS Type of Study: Meta-analysis of Phase 3 clinical trials Endpoint: Evaluate OS and PFS in Quadruplet vs Triplet therapy Search strategy: PRISMA protocol using keywords ((“multiple myeloma”[Title/Abstract] AND (“quadruple therapy”[Title/Abstract] OR “triple therapy”[Title/Abstract] OR (“bortezomib-lenalidomide-dexamethasone”[All Fields] AND “VRd”[Title/Abstract]) OR (“lenalidomide-dexamethasone”[All Fields] AND “Rd”[Title/Abstract]) OR (“bortezomib-melphalan-prednisone”[All Fields] AND “VMP”[Title/Abstract]) OR (“CD38-targeted”[All Fields] AND “antibody”[Title/Abstract]))) NOT “Transplant-eligible”[All Fields]) AND ((y_10[Filter]) AND (clinicaltrial[Filter] OR clinicaltrialphasei[Filter] OR clinicaltrialphaseii[Filter] OR clinicaltrialphaseiii[Filter] OR clinicaltrialphaseiv[Filter] OR multicenterstudy[Filter] OR observationalstudy[Filter] OR randomizedcontrolledtrial[Filter]) AND (fft[Filter]) AND (humans[Filter]) AND (english[Filter])) to identify clinical trials from last 10 years. Inclusion criteria: Only Clinical trials recruited TIMM patients in the last 10 yearsExclusion criteria: Studies other than clinical trials, non-human, non-English, and non-full text studies were excluded. Study selection & Data extraction: Using eligibility criteria and keywords, we screened the abstracts and evaluated them for their inclusion in our meta-analysis. From screen abstracts, full-length articles were obtained and studied individually for their eligibility in quantitative analysis (meta-analysis). Data on study name, design, country, duration, sample size, population characteristics [country, mean/median age, sex], type of intervention, and outcomes (OS and PFS) were collected. Statistical analysis: Review Manager 5.3 software was used to analyze the data. We performed random effects models to estimate the pooled effect size (pooled odds ratio) and 95% confidence interval (95% CI). Forest plots were obtained. p75% represented high heterogeneity. Risk of bias analysis was performed using the Newcastle-Ottawa Scale. RESULTS Out of 51 studies, fulfilling the criteria, nine studies had data on the management of TIMM, of which five studies had data on outcomes of Quadruplet vs Triplet therapy. ALCYONE, IMROZ, and OCTANS were the main multicenter, randomized, and open-label clinical trials covering 160+ sites in 25+ countries. We found 607 patients (of 1196) on Quadruplet and 368 patients (of 1142) on Triplet therapy. Quadruplet therapy had 88% higher odds of OS [OR: 1.88, 95%CI: 1.51-2.35, p<0.00001, I2: 0%] and 178% higher odds of PFS [2.78, 0.83-9.33, p=0.1, I2: 92%] in compared to Triplet therapy. [Pooled OR for survival: 2.30, 1.36-3.87, p=0.002, I2: 0%]. Quadruplet therapy had higher odds of MRD negative [4.04, 2.32-7.03, p<0.00001, I2: 52%] and RR [2.25, 1.66-3.05, p<0.00001, I2: 0%] in compared to Triplet therapy. NOS suggested a moderate risk of bias. CONCLUSION In conclusion, our meta-analysis demonstrates that Quadruplet therapy significantly outperforms Triplet therapy in transplant-ineligible multiple myeloma patients, with notable improvements in overall survival and progression-free survival. The Quadruplet regimen also enhances the likelihood of achieving minimal residual disease negativity and a higher response rate. These findings underscore the potential benefits of integrating an additional drug into treatment regimens for better clinical outcomes.

25 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
VRVirendrasinh Ravat
Virendrasinh Ravat
TATemitope Ajibawo
Temitope Ajibawo
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
KPKristal N. Pereira
Kristal N. Pereira
TYTing Yu Yen
Ting Yu Yen
Rikinkumar S. PatelRikinkumar S. Patel
Rikinkumar S. Patel
To study the trends of arrhythmia hospitalizations with comorbid alcohol use disorders (AUDs) in terms of demographic characteristics and inpatient outcomes. We used the Nationwide Inpatient Sample (NIS) data from 2010 to 2014 and included 570,556 arrhythmia inpatients (age, 15-54 years), and 55,730 inpatients had comorbid AUD. We used the linear-by-linear association test for measuring the differences in demographics, comorbidities, and hospital outcomes over the study period of 2010 to 2014, and the analysis of variance (ANOVA) for measuring the changes seen in the length of stay (LOS) and total charges. Arrhythmia inpatients with AUD were majorly males (85.9%), and older-age adults (45 to 54 years, 68%). Hypertension (52.2%), tobacco abuse (42.3%), and elevated cholesterol and lipids (22.6%) were the most prevalent comorbidities in the study population. There was a statistically significant increasing trend in arrhythmia inpatients with AUD with comorbid diabetes, hypertension, and obesity over the five-year period. In-hospital mortality had a variable trend from 1.1% in 2010 to 1.3% in 2014, but there was a statistically non-significant difference in the trend (P = 0.418). Mean LOS was three days with statistically no significant change during the study period (P = 0.080), whereas total charges have been increasing significantly (P <0.001), averaging $37,473 per hospitalization. The prevalence trend of arrhythmia hospitalizations with comorbid AUD is increasing in the United States population, and is majorly seen in older-age men. Overall, in-hospital mortality in arrhythmia inpatients with comorbid AUD was 1.4%. So, this necessitates the development of an integrated clinical care model for early diagnosis and management of alcohol abuse and dependence in order to improve the arrhythmia patient outcomes and quality of life.

5 November 2024 in Blood
Verified
Journal Article
Closed access
MPMegha Panchal
Megha Panchal
JAJanani Arunachalam
Janani Arunachalam
AMAhsan Memon
Ahsan Memon
HPHashwin Pilathodan
Hashwin Pilathodan
KSKeerthi Sripathi
Keerthi Sripathi
TARUN PARVATANENITARUN PARVATANENI
TARUN PARVATANENI
INTRODUCTION Primary pulmonary lymphoma (PPL) is an uncommon form of non-Hodgkin lymphoma that begins in the lungs. PPL originates directly within the lung tissue, unlike more prevalent lymphomas that frequently metastasize to the lungs from other sites. Lung primary non-Hodgkin lymphoma (NHL) is an exceptionally uncommon condition, representing approximately 0.4% of all malignant lymphomas. Only 3-4% of non-Hodgkin lymphoma (NHL) that does not start in lymph nodes is primary pulmonary lymphoma (PPL). This is less than 1% of all NHL cases and 0.5-1% of all primary lung cancers. Here we present a rare case of primary pulmonary follicular lymphoma characterized by bilateral pleural effusion. AIM The main objective in managing primary pulmonary lymphoma (PPL) is to promptly identify, precisely diagnose, and efficiently treat the condition to enhance patient outcomes. This entails increasing knowledge, employing sophisticated diagnostic methods, precisely determining the stage of the disease, and creating personalized treatment strategies. CASE REPORT A 74-year-old male patient presented with shortness of breath that was progressively worsening for 3 to 4 weeks. The patient denied having fever, chills, sweating, unexpected weight loss, or lymphadenopathy in the armpit, neck, or groin. The patient had no prior history of lung disease, and he did not use home oxygen or inhalers. The patient smoked up to 1 pack of cigarettes daily for 10 years but quit in 1995. He was initially treated with antibiotics, but the dyspnea persisted. A chest X-ray and CT angiogram were done at the time, which displayed bilateral pleural effusions, moderate on the right and small on the left, and no evidence of pulmonary thromboembolic disease. Therapeutic and diagnostic aspirations had been made. The cytology of the fluid was suggestive of exudative and found negative for malignant cells. Despite initial negative cytology for malignant cells, the patient returned 2 weeks later with dyspnea and increased bilateral pleural effusions from prior studies. A second thoracocentesis and analysis of the fluid, using flow cytometry and FISH, showed a single group of B cells that were positive for lambda CD10. This is a sign of follicular lymphoma, which is supported by changes in BCL6, BCL2, and t(14:18)/IGH-BCL2. CONCLUSION In summary, this case adds to the existing knowledge about the various ways NHL can present and supports the need for a comprehensive approach to caring for patients with pleural effusion. It also highlights the importance of early detection and prompt initiation of treatment for unexpected cancer cases, improving results through focused therapeutic approaches.